Mankind Pharma announced an update on the credit ratings of its financial instruments. The credit rating for commercial paper has been withdrawn. Ratings for non-convertible debentures and long-term/short-term fund-based limits remain outstanding. The information is available on the company’s website. The ratings reflect independent assessments of Mankind Pharma’s creditworthiness and financial stability.
Credit Rating Changes
Mankind Pharma announced changes to the credit ratings of some of its financial instruments.
Commercial Paper
The credit rating for the company’s commercial paper, previously rated (ICRA) A1+, has been officially withdrawn.
Outstanding Ratings
The company also confirmed the outstanding credit ratings for its other financial instruments:
- Non-Convertible Debentures: Rated (ICRA) AA+/Stable, reflecting an outstanding rating. The amount is ₹5,000 crore.
- Long-term/Short term fund based limits: Rated (ICRA)AA+ (Stable)/(ICRA)A1+, reflecting an outstanding rating. The amount is ₹1,250 crore.
Additional Information
Further details about the credit ratings and related information are available on Mankind Pharma’s official website.
Source: BSE
